

Special Issue

Vaccines and Therapeutic Approaches in Dermatological Diseases

Message from the Guest Editors

Diseases and deaths can be prevented by vaccines. Vaccines have often been developed to fight bacterial and viral diseases, most recently against COVID-19. In recent years, vaccines against solid tumors and skin cancer have seen increased development. In allergology, vaccines are also successfully used for hyposensitisation against certain allergens. The vaccines modify the immune system by interacting with the antigen, DNA, RNA or allergen and triggering a B- and T-cell response. Vaccinations have also been associated with cutaneous reactions in the past. Thus, "Vaccines and Therapeutic Approaches in Dermatological Diseases" is an important research topic. This Special Issue welcomes all articles, reviews, meta-analyses and diagnostic methods that shed new light on the mechanisms and therapeutic approaches in dermatological diseases. We look forward to receiving contributions that address potential targets of future vaccines in dermatological diseases. Contributions describing cutaneous vaccination reactions and complications are also welcome.

Guest Editors

Prof. Dr. Thilo Gambichler

1. Department of Dermatology, Dortmund Hospital, University Witten/Herdecke, 44137 Dortmund, Germany
2. Department of Dermatology and Phlebology, Christian Hospital Unna, 59423 Unna, Germany

Dr. Nessr Abu Rached

1. International Centre for Hidradenitis Suppurativa/Acne Inversa, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, Germany
2. Skin Cancer Center, Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, Germany

Deadline for manuscript submissions

closed (31 December 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/168116

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).